Baxter 2B0973 - Lidocaine Hydrochloride, 5% Dextrose Injection, USP, 2 grams/ 500 ml (4 mg/ml), Viaflex Plastic Container, Liquid Premix, 18/cs (Rx) (Continental US Only, Excluding IN and ND)
Baxter 2B0973 Lidocaine Hydrochloride, 5% Dextrose Injection, USP, 2 grams/ 500 ml (4 mg/ml), Viaflex Plastic Container, Liquid Premix
Lidocaine Hydrochloride and 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution prepared from lidocaine hydrochloride and dextrose in water for injection. It contains no antimicrobial agents. Lidocaine hydrochloride is designated chemically as 2-(Diethylamino) - 2', 6' - acetoxylidide monohydrochloride. The solution serves as a cardiac antiarrhythmic agent intended for intravenous use. Composition, osmolarity, pH and caloric content are shown in Table 1. The pH is adjusted with sodium hydroxide.
- Injection solution comes in a Viaflex Plus plastic container
- 18-month shelf life
- Store at 25 degree celsius
| Composition | Osmolarity (mOsmol/L) (calc) | pH | Caloric Content (kcal/L) | ||
| Lidocaine Hydrochloride, USP (mg/mL) | Dextrose Hydrous, USP (g/L) | ||||
| 0.4% Lidocaine Hydrochloride and 5% Dextrose Injection, USP | 4 | 50 | 282 | 4.0 (3.0 to 7.0) | 170 |
| 0.8% Lidocaine Hydrochloride and 5% Dextrose Injection, USP | 8 | 50 | 311 | 4.0 (3.0 to 7.0) | 170 |
This VIAFLEX Plus plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). VIAFLEX Plus on the container indicates the presence of a drug additive in a drug vehicle. The VIAFLEX Plus plastic container system utilizes the same container as the VIAFLEX plastic container system. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological standards for plastic containers as well as by tissue culture toxicity studies.
Baxter 2B0973 Indications and Usage
Lidocaine hydrochloride administered intravenously is specifically indicated in the acute management of (1) ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery and (2) life-threatening arrhythmias which are ventricular in origin, such as occur during acute myocardial infarction.
| Code | Size (mL) | Product Name |
| 2B0972 | 250 | Lidocaine Hydrochloride and 5% Dextrose |
| 2B0973 | 500 | Injection, USP (4 mg/mL) |
| 2B0962 | 250 | Lidocaine Hydrochloride and 5% Dextrose Injection, USP (8 mg/mL) |
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25 degree celsius); brief exposure up to 40 degree celsius does not adversely affect the product.
Baxter 2B0973 Contraindications
Hypersensitivity reactions, including anaphylactic reactions, have been reported with lidocaine. Lidocaine hydrochloride is contraindicated in patients with a history of hypersensitivity to local anesthetics of the amide type.
Lidocaine is contraindicated in patients with Stokes-Adams syndrome, Wolff-Parkinson-White syndrome, or with severe degrees of sinoatrial, atrioventricular, or intraventricular block.
Baxter #2B0962, Lidocaine Hydrochloride, 5% Dextrose Injection, USP, 2 grams/ 250 ml (8 mg/ml), Viaflex Plastic Container, Liquid Premix, 24/cs (Rx) (Continental US Only, Excluding IN and ND)
